Lenalidomide at the Dose of Twenty-five mg Every Other Day in Patients Affected by Multiple Myeloma and Renal Failure: A Real-life Experience

2017 ◽  
Vol 17 (1) ◽  
pp. e122
Author(s):  
Claudio Cerchione ◽  
Lucio Catalano ◽  
Anna Emanuele Pareto ◽  
Davide Nappi ◽  
Ilaria Peluso ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Life Experience ◽  
Real Life

Full Standard Doses of Lenalidomide in Bortezomib-Refractory Multiple Myeloma Patients Affected by Renal Failure: A Real-Life Experience

2017 ◽  
Vol 17 ◽  
pp. S342-S343
Author(s):  
Claudio Cerchione ◽  
Lucio Catalano ◽  
Anna Emanuela Pareto ◽  
Davide Nappi ◽  
Ilaria Peluso ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Life Experience ◽  
Real Life ◽  
Refractory Multiple Myeloma

Bendamustine-Bortezomib-Dexametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience

2017 ◽  
Vol 17 ◽  
pp. S343
Author(s):  
Claudio Cerchione ◽  
Lucio Catalano ◽  
Anna Emanuele Pareto ◽  
Santina Basile ◽  
Luana Marano ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Life Experience ◽  
Real Life ◽  
Refractory Multiple Myeloma

scholarly journals Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5713-5713
Author(s):  
Claudio Cerchione ◽  
Lucio Catalano ◽  
Anna Emanuele Pareto ◽  
Santina Basile ◽  
Luana Marano ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Life Experience ◽  
Conflicts Of Interest ◽  
Real Life ◽  
Antiemetic Drugs ◽  
Impressive Result ◽  
Significant Efficacy ◽  
Low Toxicity ◽  
Grade 3

Abstract Introduction : Bendamustine is a bifunctional alkylating agent, with low toxicity, proved to be effective in relapsed, refractory and in new diagnosed Multiple Myeloma (MM). It has been evaluated efficacy and tolerance of Bendamustine, in combination with bortezomib-dexamethasone (BVD) in patients with relapsed and refractory MM (rrMM), whose prognosis is particularly severe. A regional retrospective real-life analysis of patients with rrMM who had been treated with BVD as salvage therapy has been performed. Methods : 56 patients (31 M/25 F), with rrMM, median age at diagnosis 57.3 years (r. 36-82), median age at start of treatment 61.8 years (r.37-83) treated with several lines of treatments (median 6, r. 2-11), every refractory to all the drugs previously received (also Bortezomib), received BVD (Bendamustine 90 mg/sqm days 1,2; Bortezomib 1.3 mg/sqm days 1,4,8,11, Dexamethasone 20 mg days 1,2,4,5,8,9,11,12, Pegfilgrastim day +4) every 28 days, until progression. ISS was equally distributed, and cytogenetic was evaluable in 12 patients, and in particular one del13q and one t(11;14). All the patients had previously been treated with schedule containing bortezomib and IMIDs, and 30% had also received radiotherapy. 67% of them had undergone at least to a single auSCT. All patients were relapsed and refractory to last therapies received before BVD. Results : Bendamustine was well tolerated, with grade 3 transfusion-dependent anemia in 41% of patients, and 37% grade 3 neutropenia (no ospedalization was required, no septic shocks were observed). No severe extrahematologic toxicity was observed, only grade 1 gastrointestinal side effect (nausea), treated by common antiemetic drugs. According to IMWG, after a median follow-up of 14 months (r.2-36), ORR was 64% (36/56: 4 CR, 7 VGPR, 16 PR, 9 MR) with 8 PD and 12 patients in SD, which can be considered as an impressive result in this subset of rrMM patients. In particular, for 11 patients, BVD was, after having achieved at least a PR, a bridge to second auSCT, and for two patients a bridge to alloSCT. Median time to response was 1.2 months (range, 1-3), median OS from diagnosis was 62.7 months (range, 6-151), median OS from start of Bendamustine was 9.8 months (range 2-36). Conclusion : BVD has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, and, in particular cases, it could be considered as a bridge to a second autologous or allogenic SCT. Disclosures No relevant conflicts of interest to declare.

scholarly journals Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5391-5391
Author(s):  
Claudio Cerchione ◽  
Lucio Catalano ◽  
Anna Emanuele Pareto ◽  
Santina Basile ◽  
Luana Marano ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Life Experience ◽  
Conflicts Of Interest ◽  
Real Life ◽  
Antiemetic Drugs ◽  
Impressive Result ◽  
Significant Efficacy ◽  
Low Toxicity ◽  
Grade 3

Abstract Introduction: Bendamustine is a bifunctional alkylating agent, with low toxicity, proved to be effective in relapsed, refractory and in new diagnosed Multiple Myeloma (MM). It has been evaluated efficacy and tolerance of Bendamustine, in combination with bortezomib-dexametasone (BVD) in patients with relapsed and refractory MM (rrMM), whose prognosis is particularly severe. A regional retrospective real-life analysis of patients with rrMM who had been treated with BVD as salvage therapy has been performed. Methods: 35 patients (19 M/16 F), with rrMM, median age at diagnosis 57 years (r. 36-82), median age at start of treatment 62 years (r.37-83) treated with several lines of treatments (median 6, r. 2-11), every refractory to all the drugs previously received (also Bortezomib), received BVD (Bendamustine 90mg/sqm days 1,2; Bortezomib 1.3mg/sqm days 1,4,8,11, Desametasone 20mg days 1,2,4,5,8,9,11,12, Pegfilgrastim day +4) every 28 days, until progression. ISS was equally distributed, and cytogenetic was evaluable in 9 patients, and in particular one del13q and one t(11;14). All the patients had previously been treated with schedule containing bortezomib and IMIDs, 90% of them with melphalan, 77% with cyclophosphamide, 34% with antracyclines and 30% had also received radiotherapy. 58% of them had undergone at least to a single auSCT. All patients were relapsed and refractory to last therapies received before BVD. Results: Bendamustine was well tolerated, with grade 3 transfusion-dependent anemia in 29% of patients, and 41% grade 3 neutropenia (no ospedalization was required, no septic shocks were observed). No severe extrahematologic toxicity was observed, only grade 1 gastrointestinal side effect (nausea), treated by common antiemetic drugs. According to IMWG, after a median follow-up of 9 months (r.2-36), ORR was 54% (1 CR, 1 VGPR, 9 PR, 8 MR) with 7 PD and 9 patients in SD, which can be considered as an impressive result in this subset of rrMM patients. In particular, for 4 patients, BVD was, after having achieved a PR, a bridge to second auSCT, and for one patient a bridge to auSCT. Median OS from diagnosis was 61.4 months (range 6-151), median OS from start of Bendamustine was 7.2 months (range 2-36). Conclusion: BVD has shown significant efficacy (ORR 54%) in a particular severe setting of patients, relapsed and refractory to all avaiable therapeutic resources, and in particular cases it could be considered as a bridge to a second autologous or allogenic BMT. Disclosures No relevant conflicts of interest to declare.

Bendamustine-Bortezomib-Dexamethasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience

2017 ◽  
Vol 17 (1) ◽  
pp. e60-e61
Author(s):  
Claudio Cerchione ◽  
Lucio Catalano ◽  
Anna Emanuele Pareto ◽  
Santina Basile ◽  
Luana Marano ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Life Experience ◽  
Real Life ◽  
Refractory Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document